← Browse by Condition
Medical Condition
triple negative breast neoplasms
Total Trials
4
Recruiting Now
4
Trial Phases
Phase 2, Phase 3, Phase 1, Phase 2
NCT06385990 Phase 2
Recruiting
Utidelone (UTD1) Plus Capecitabine in Non-pCR TNBC After Neoadjuvant Therapy
Enrollment
53 pts
Location
China
Sponsor
Hunan Cancer Hospital
NCT06841354 Phase 3
Recruiting
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
Enrollment
1,000 pts
Location
United States, Argen...
Sponsor
Merck Sharp & Dohme LLC
NCT06966700 Phase 3
Recruiting
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Enrollment
2,400 pts
Location
United States, Argen...
Sponsor
Merck Sharp & Dohme LLC
NCT06380816 Phase 1, Phase 2
Recruiting
A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer
Enrollment
167 pts
Location
United Kingdom
Sponsor
Cancer Research UK